A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

January 16, 2018

Primary Completion Date

March 26, 2020

Study Completion Date

June 11, 2020

Conditions
Diabetic Macular Edema
Interventions
BIOLOGICAL

Aflibercept

Intravitreal injection

BIOLOGICAL

OPT-302

Intravitreal Injection

OTHER

Sham intravitreal injection

Sham (mock) intravitreal injection

Trial Locations (53)

2145

Opthea Investigational Site, Westmead

15208

Opthea Investigational Site, Tiberias

21740

Opthea Investigational Site, Hagerstown

28210

Opthea Investigational Site, Charlotte

28803

Opthea Investigational Site, Asheville

29169

Opthea Investigational Site, West Columbia

29414

Opthea Investigational Site, Charleston

30909

Opthea Investigational Site, Colorado Springs

Opthea Investigational Site, Augusta

31048

Opthea Investigational Site, Haifa

31096

Opthea Investigational Site, Haifa

32503

Opthea Investigational Site, Pensacola

32901

Opthea Investigational Site, Melbourne

33426

Opthea Investigational Site, Boynton Beach

33711

Opthea Investigational Site, St. Petersburg

33912

Opthea Investigational Site, Fort Myers

34362

Opthea Investigational Site, Haifa

38138

Opthea Investigational Site, Germantown

44281

Opthea Investigational Site, Kfar Saba

46290

Opthea Investigational Site, Indianapolis

49100

Opthea Investigational Site, Petah Tikva

50266

Opthea Investigational Site, Des Moines

57701

Opthea Investigational Site, Rapid City

64239

Opthea Investigational Site, Tel Aviv

67214

Opthea Investigational Site, Wichita

76012

Opthea Investigational Site, Arlington

76087

Opthea Investigational Site, Willow Park

76100

Opthea Investigational Site, Rehovot

77030

Opthea Investigational Site, Houston

78240

Opthea Investigational Site, San Antonio

78503

Opthea Investigational Site, McAllen

78705

Opthea Investigational Site, Austin

79606

Opthea Investigational Site, Abilene

85014

Opthea Investigational Site, Phoenix

89144

Opthea Investigational Site, Las Vegas

89502

Opthea Investigational Site, Reno

90211

Opthea Investigational Site, Beverly Hills

91031

Opthea Investigational Site, Jerusalem

91120

Opthea Investigational Site, Jerusalem

92374

Opthea Investigational Site, Redlands

92705

Opthea Investigational Site, Santa Ana

Opthea Investigational Site, Youngstown

93309

Opthea Investigational Site, Bakersfield

95819

Opthea Investigational Site, Sacramento

97213

Opthea Investigational Site, Portland

Unknown

Opthea Investigational Site, Parramatta

Opthea Investigational Site, Sydney

Opthea Investigational Site, Perth

703 5

Opthea Investigational Site, Be’er Ya‘aqov

LV-3001

Opthea Investigational Site, Jelgava

LV-1002

Opthea Investigational Site, Riga

LV-1006

Opthea Investigational Site, Riga

LV-1050

Opthea Investigational Site, Riga

All Listed Sponsors
lead

Opthea Limited

INDUSTRY

NCT03397264 - A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema | Biotech Hunter | Biotech Hunter